Advances in treatment of cholesterol abnormalities

References

• Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea. JAMA 1953; 152:1090–3
   PubMed Web of Science ®Google Scholar
• McNamara JJ, Molot MA, Stremple JF, et al. Coronary artery disease in combat casualties in Vietnam. JAMA 1971; 216(7): 1185–7
   PubMedGoogle Scholar
• Joseph A, Ackerman D, Talley JD, et al. Manifestations of coronary atherosclerosis in young trauma victims: an autopsy study. J Am Coll Cardiol 1993; 22(2): 459–67
   Google Scholar
• Anitschkow NN. A history of experimentation on atherosclerosis in animals. In: Blumenthal HT, Cowdry EV, eds. Arteriosclerosis: a survey of the problem. 2d ed. Springfield, IL: Thomas, 1967; 21–44
   Google Scholar
• Rackley CE. Monotherapy with HMG Co-A reductase inhibitors in secondary prevention and coronary artery disease. Clin Cardiol 1996; 19(Sep): 683
   Google Scholar
• Cohen MV, Byrne MJ, Levine B, et al. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83(4): 1294–304
   PubMed Web of Science ®Google Scholar
• The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148(1): 36–69
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP). Arch Intern Med 1993; 269(23): 3015–23
   Google Scholar
• Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110(5): 1100–7
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982; 248(12): 1465–77
   PubMed Web of Science ®Google Scholar
• Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994; 73(14): 3–11D [Erratum, Am J Cardiol 1994: 74(6): 639]
   PubMed Web of Science ®Google Scholar
• Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29(7–8): 743–59
   Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323(19): 1289–98
   PubMed Web of Science ®Google Scholar
• Blankenhom DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993; 119(10): 969–76
   Google Scholar
• Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. Circulation 1994; 89(3): 959–68
   PubMedGoogle Scholar
• Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26(5): 1133–9
   PubMed Web of Science ®Google Scholar
• Jukcma JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995; 91(10): 2528–40
   Google Scholar
• The Multicentre Anti-Atheroma Study (MAAS) investigators. Effect of simvastatin on coronary atheroma. Lancet 1994; 344(8923): 633–8 [Erratum, Lancet 1994; 344(8924):762]
   Google Scholar
• Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90(4): 1679–87
   PubMed Web of Science ®Google Scholar
• Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75(7): 455–9 [Erratum, Am J Cardiol 1995: 75(12): 862
   PubMedGoogle Scholar
• Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92(7): 1758–64
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317(20): 1237–45
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results II. The relation ship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251(3): 365–74
   PubMed Web of Science ®Google Scholar
• The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease. Lancet 1994; 344(8934): 1383–9
   PubMed Web of Science ®Google Scholar
• Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78(5 Pt 1): 1157–66
   PubMed Web of Science ®Google Scholar
• Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12(1): 56–62
   PubMed Web of Science ®Google Scholar
• Rackley CE, Kuhn F. Cardiac rehabilitation/risk factor modification. In: Gersh BJ, Rahimtoola SA, eds. Acute myocardial infarction. New York: Chapman & Hall (in press)
   Google Scholar
• Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344(8925): 793–5
   PubMed Web of Science ®Google Scholar
• Kaski JC, Chester MR, Chen L, et al. Rapid angiographic progression of coronary artery disease in patients with angina pectoris: the role of complex stenosis morphology. Circulation 1995; 92(8): 2058–65
   Google Scholar
• Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991; 68(15): 1425–30
   Web of Science ®Google Scholar
• Bui MN, Sack MN, Moutsatsos G, et al. Autoantibody titres to oxidized low density lipoprotein in patients with coronary atherosclerosis. Am Heart J 1996; 131:663–7
   Google Scholar
• Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92(4): 748–55
   Google Scholar
• Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms, oxidation, inflammation, and genetics. Circulation 1995; 91(9): 2488–96
   PubMed Web of Science ®Google Scholar
• Goldman L, Weinstein MC, Goldman PA, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265(9): 1145–51
   PubMed Web of Science ®Google Scholar
• Reckless PD. The 4S study and its pharmacoeconomic implications. Pharmacoeconomics 1996; 9(2): 101–5
   Google Scholar
• Kinosian B, Glick H, Schwartz JS. Scandinavian Simvastatin Survival Study (4S): cost effectiveness of cholesterol lowering treatment. J Am Coll Cardiol 1996; 27(Suppl 2): 165A
   Google Scholar